TWI880924B - 製備(6r,10s)-10-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-側氧基-1(6h)-嘧啶基}-1-(二氟甲基)-6-甲基-1,4,7,8,9,10-六氫-11,15-(亞甲橋基)吡唑并[4,3-b][1,7]二氮雜環十四炔-5(6h)-酮之新穎合成選項 - Google Patents
製備(6r,10s)-10-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-側氧基-1(6h)-嘧啶基}-1-(二氟甲基)-6-甲基-1,4,7,8,9,10-六氫-11,15-(亞甲橋基)吡唑并[4,3-b][1,7]二氮雜環十四炔-5(6h)-酮之新穎合成選項 Download PDFInfo
- Publication number
- TWI880924B TWI880924B TW109112263A TW109112263A TWI880924B TW I880924 B TWI880924 B TW I880924B TW 109112263 A TW109112263 A TW 109112263A TW 109112263 A TW109112263 A TW 109112263A TW I880924 B TWI880924 B TW I880924B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- acid
- alkyl
- added
- generate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832614P | 2019-04-11 | 2019-04-11 | |
| US62/832,614 | 2019-04-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202104188A TW202104188A (zh) | 2021-02-01 |
| TWI880924B true TWI880924B (zh) | 2025-04-21 |
Family
ID=70457148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109112263A TWI880924B (zh) | 2019-04-11 | 2020-04-10 | 製備(6r,10s)-10-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-側氧基-1(6h)-嘧啶基}-1-(二氟甲基)-6-甲基-1,4,7,8,9,10-六氫-11,15-(亞甲橋基)吡唑并[4,3-b][1,7]二氮雜環十四炔-5(6h)-酮之新穎合成選項 |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11788071B2 (en) | 2020-04-10 | 2023-10-17 | Codexis, Inc. | Engineered transaminase polypeptides |
| EP4225757A1 (en) * | 2020-10-12 | 2023-08-16 | Bristol-Myers Squibb Company | A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613923A (en) * | 2014-10-01 | 2016-04-16 | Bristol Myers Squibb Co | Pyrimidinones as factor XIA inhibitors |
| WO2018133793A1 (zh) * | 2017-01-18 | 2018-07-26 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013033777A2 (pt) * | 2011-03-15 | 2016-09-13 | Abbvie Inc | moduladores de receptor de hormônio nuclear |
| JP6505727B2 (ja) | 2014-01-31 | 2019-04-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| CN105294496A (zh) | 2015-09-28 | 2016-02-03 | 中山大学 | 一种西酞普兰中间体的制备方法 |
| CN113677682B (zh) | 2019-04-16 | 2023-05-30 | 华润生物医药有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| WO2021013209A1 (zh) | 2019-07-23 | 2021-01-28 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| CA3179679A1 (en) | 2020-04-10 | 2021-10-14 | Codexis, Inc. | Carboxyesterase polypeptides for kinetic resolution |
-
2020
- 2020-04-10 EP EP23169596.6A patent/EP4234555A3/en active Pending
- 2020-04-10 CN CN202080041935.8A patent/CN114375290B/zh active Active
- 2020-04-10 CA CA3132365A patent/CA3132365A1/en active Pending
- 2020-04-10 ES ES20721374T patent/ES2969253T3/es active Active
- 2020-04-10 JP JP2021559890A patent/JP7631218B2/ja active Active
- 2020-04-10 EA EA202192807A patent/EA202192807A1/ru unknown
- 2020-04-10 BR BR112021020368A patent/BR112021020368A2/pt unknown
- 2020-04-10 IL IL287102A patent/IL287102B2/en unknown
- 2020-04-10 MX MX2025014306A patent/MX2025014306A/es unknown
- 2020-04-10 MX MX2021012286A patent/MX2021012286A/es unknown
- 2020-04-10 TW TW109112263A patent/TWI880924B/zh active
- 2020-04-10 KR KR1020267004972A patent/KR20260047658A/ko active Pending
- 2020-04-10 AU AU2020272973A patent/AU2020272973B2/en active Active
- 2020-04-10 WO PCT/US2020/027655 patent/WO2020210613A1/en not_active Ceased
- 2020-04-10 KR KR1020217036807A patent/KR102929951B1/ko active Active
- 2020-04-10 SG SG11202111132WA patent/SG11202111132WA/en unknown
- 2020-04-10 CN CN202411615118.5A patent/CN119775276A/zh active Pending
- 2020-04-10 US US17/602,059 patent/US12378246B2/en active Active
- 2020-04-10 EP EP20721374.5A patent/EP3953334B1/en active Active
- 2020-04-13 AR ARP200101024A patent/AR118649A1/es unknown
-
2025
- 2025-02-05 JP JP2025017468A patent/JP7885383B2/ja active Active
- 2025-06-18 US US19/242,506 patent/US20260092066A1/en active Pending
-
2026
- 2026-02-25 AU AU2026201396A patent/AU2026201396A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613923A (en) * | 2014-10-01 | 2016-04-16 | Bristol Myers Squibb Co | Pyrimidinones as factor XIA inhibitors |
| WO2018133793A1 (zh) * | 2017-01-18 | 2018-07-26 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3740050B2 (ja) | ケトンの還元用キラル触媒とその製法 | |
| AU2026201396A1 (en) | Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one | |
| WO2021254896A1 (en) | Process for preparing (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide enabled by a catalytic asymmetric hantzsch ester reduction | |
| CA3195024A1 (en) | A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b] [1,7]diazacyclotetradecin-5(6h)-one | |
| JP6368351B2 (ja) | ジフルオロラクタムアナログを合成する方法 | |
| EP0826652B1 (en) | Process for preparing asymmetric compound by using metal complex | |
| WO2002022618A1 (fr) | Preparation de la camptothecine et de ses derives | |
| EA050867B1 (ru) | СПОСОБ ПОЛУЧЕНИЯ (6R,10S)-10-{4-[5-ХЛОРО-2-(4-ХЛОРО-1Н-1,2,3-ТРИАЗОЛ-1-ИЛ)ФЕНИЛ]-6-ОКСО-1(6Н)-ПИРИМИДИНИЛ}-1-(ДИФТОРОМЕТИЛ)-6-МЕТИЛ-1,4,7,8,9,10-ГЕКСАГИДРО-11,15-(МЕТЕНО)ПИРАЗОЛО[4,3-b][1,7]ДИАЗАЦИКЛОТЕТРАДЕЦИН-5(6Н)-ОНА | |
| CS354591A3 (en) | Aminodiole derivatives, process of their preparation and their use | |
| CN114163445A (zh) | 拉罗替尼中间体及其制备方法 | |
| HK40124045A (en) | Novel synthetic options towards the manufacture of a compound | |
| JP3610014B2 (ja) | 不斉水素化のための改良された製法 | |
| KR101519011B1 (ko) | 비스무트 촉매를 이용한 피라노쿠마린 유도체의 제조방법 | |
| EP1519930B1 (en) | Benzoprostacyclin intermediates and methods for their preparation | |
| JP4524845B2 (ja) | アミノ基を有する光学活性アリルアルコール誘導体の製造方法、および光学活性化合物 | |
| JP5981747B2 (ja) | アザディールス−アルダー反応用触媒、それを用いたテトラヒドロピリジン化合物の製造方法 | |
| CN117377660A (zh) | 用于苯并氧氮杂䓬恶唑烷酮化合物的制备的方法 | |
| HK40053273B (en) | Method for preparing 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine | |
| JP2009132650A (ja) | イソオキサゾリジン化合物 | |
| KR20010083068A (ko) | 4-치환된-1h-피롤-3-카복실산 에스테르의 새로운 제조방법 |